Sigachi Industries shares rebounded after announcing progress on a new combination of APIs for Cystic Fibrosis, projecting revenue of ₹250 cr annually by FY2026-27. The move enhances growth potential in a market expected to exceed USD 10 bln, focusing on innovative treatments for rare diseases.
